Article PDF first page preview

First page of Postoperative Outcomes and Prognostic Factors of High Myopia Epiretinal Membrane Associated with Retinoschisis After Vitrectomy

Introduction: The outcomes and prognosis of pars plana vitrectomy (PPV) for high myopia epiretinal membranes (HM-ERM) patients with retinoschisis remains unclear. To analyze the impact of retinoschisis on the recovery of macular configuration and visual acuity following ERM removal in eyes with HM and to explore the prognostic factors. Methods: A retrospective study of 73 consecutive patients with HM-ERM who underwent PPV with ERM peeling. According to the optical coherence tomography images, eyes were classified into 4 groups: group A without retinoschisis, group B with outer retinoschisis, group C with inner retinoschisis, group D with both inner and outer retinoschisis. Results: In Groups A, B, C, and D, there were 17, 21, 22, and 16 eyes, respectively. Retinoschisis of 44 eyes (74.6%) disappeared postoperatively, including 13 eyes in group B, 20 in group C, and 9 in group D. A significant difference in the resolution of retinoschisis was observed between Groups C and D (P=0.036). No correlation was found between retinoschisis resolution and baseline factors. The mean best-corrected visual acuity (BCVA) significantly improved at the final follow-up (P＜0.001). The final BCVA was associated with baseline BCVA (P=0.007), the presence of epiretinal proliferation preoperatively (P=0.008) , and ithe postoperative integrity of the ellipsoid zone (EZ) (P<0.001) and interdigitation zone (IZ) (P=0.001). Conclusions: After surgery, the inner retinoschisis usually resolved completely. Retinoschisis was not the main factor influencing final BCVA. Preoperative BCVA and disruption of EZ and IZ were associated with good visual recovery in long-term follow-up.

Journal Section:
Retina
This content is only available via PDF.
The Author(s). Published by S. Karger AG, Basel
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License .
Attribution-NonCommercial